Abstract: Pemphigus is a chronic, recurrent and serious epidermolysis bullous skin disease. Biological agents and bioengineering technology play a certain role in the treatment of pemphigus. Rituximab has been proved to play an important role in the treatment of pemphigus and is recommended as the first-line treatment by guidelines. Hematopoietic stem cell transplantation can rebuild the patient's immune system. Based on the good effect of previous clinical trials, hematopoietic stem cell transplantation has been applied to the treatment of autoimmune diseases including refractory pemphigus. Regulatory T cells (Tregs) play an important role in maintaining self tolerance and avoiding of excessive immune response. Tregs adoptive cell therapy enjoys positive effect in pemphigus and clinical trials are ongoing. The review focuses on the update of Rituximab, hematopoietic stem cell transplantation and Tregs adoptive cell therapy in the treatment of pemphigus.

Key words: pemphigus, rituximab, hematopoietic stem cell transplantation, regulatory T cell